[go: up one dir, main page]

SV2002000036A - Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma - Google Patents

Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma

Info

Publication number
SV2002000036A
SV2002000036A SV2000000036A SV2000000036A SV2002000036A SV 2002000036 A SV2002000036 A SV 2002000036A SV 2000000036 A SV2000000036 A SV 2000000036A SV 2000000036 A SV2000000036 A SV 2000000036A SV 2002000036 A SV2002000036 A SV 2002000036A
Authority
SV
El Salvador
Prior art keywords
hmg
dihydroxyl
reductase
ref
salts
Prior art date
Application number
SV2000000036A
Other languages
English (en)
Inventor
Edward J J Grabowski
Richard D Tillyer
Paul J Reider
Jose M Vega
Feng Xu
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SV2002000036A publication Critical patent/SV2002000036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL PRESENTE INVENTO OFRECE METODOS Y COMPOSICIONES FARMACEUTICAS PARA LA INHIBICION DE REDUCTASA HMG-CoA, ASI COMO EL TRATAMIENTO Y/O REDUCCION DEL RIESGO DE ENFERMEDADES Y CONDICIONES QUE AFECTAN LA INHIBICION DE REDUCTASA HMG-CoA, QUE COMPRENDE LA ADMINISTRACION ORAL DE UNA CANTIDAD EFECTIVA TERAPEUTICAMENTE DE UN COMPUESTO SELECCIONADO DE UNA ESTATINA DE ACIDO ABIERTO DE DIHIDROXILO Y UNA SAL O ESTER CORRESPONDIENTE FARMACEUTICAMENTE ACEPTABLE EN FORMA DE DOSIS FARMACEUTICA DE LIBERACION RETRASADA A UN PACIENTE QUE NECESITE DICHO TRATAMIENTO, DONDE UNA IMPORTANTE LIBERACION DEL COMPUESTO DE LA DOSIS SE RETRASA HASTA QUE LA DOSIS PASE AL ESTOMAGO.
SV2000000036A 1999-03-08 2000-03-08 Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma SV2002000036A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12322799P 1999-03-08 1999-03-08
US26474499A 1999-03-09 1999-03-09
PCT/US2000/002626 WO2000053173A1 (en) 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors

Publications (1)

Publication Number Publication Date
SV2002000036A true SV2002000036A (es) 2002-02-05

Family

ID=26821357

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000036A SV2002000036A (es) 1999-03-08 2000-03-08 Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma

Country Status (9)

Country Link
EP (1) EP1161236A1 (es)
JP (2) JP2002538202A (es)
AR (1) AR022856A1 (es)
AU (1) AU2866400A (es)
CA (1) CA2364253A1 (es)
CO (1) CO5150193A1 (es)
PE (1) PE20001559A1 (es)
SV (1) SV2002000036A (es)
WO (1) WO2000053173A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780624B2 (en) * 1999-11-04 2005-04-07 Andrx Corporation Method of treating amyloid beta precursor disorders
WO2002020457A1 (en) * 2000-09-06 2002-03-14 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
PL361097A1 (en) * 2000-10-12 2004-09-20 Nissan Chemical Industries, Ltd. Preventives and remedies for complications of diabetes
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
MEP27808A (en) 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ATE331512T1 (de) 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
CN100430405C (zh) * 2001-08-16 2008-11-05 特瓦制药工业有限公司 制备他汀类的钙盐形式的方法
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE359087T1 (de) * 2002-01-09 2007-05-15 Crucell Holland Bv Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
EP1606287B1 (en) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
WO2005046662A2 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
US10208351B2 (en) 2013-10-18 2019-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) RNY-derived small RNAs as biomarkers for atherosclerosis-related disorders
CN110709074B (zh) 2017-05-15 2023-02-17 辛辛那提大学 通过直接施用辛伐他汀的一种或多种代谢物来治疗无血管软骨组织中的缺损的组合物和方法
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
DE122011000014I1 (de) * 1995-12-22 2011-11-03 Kowa Co Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium.
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
JP2002538202A (ja) 2002-11-12
WO2000053173A1 (en) 2000-09-14
CA2364253A1 (en) 2000-09-14
AR022856A1 (es) 2002-09-04
AU2866400A (en) 2000-09-28
JP2000256191A (ja) 2000-09-19
EP1161236A1 (en) 2001-12-12
PE20001559A1 (es) 2001-01-16
CO5150193A1 (es) 2002-04-29

Similar Documents

Publication Publication Date Title
SV2002000036A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
SV2002000035A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11121/rm/ta
PL360495A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
NZ514574A (en) Novel method of treatment
MXPA04009352A (es) Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2).
CO5570677A2 (es) Quinolinilpirrolopirazoles
WO2005016326A3 (en) Analogs of thalidomide as potential angiogenesis inhibitors
WO2007126964A3 (en) Kinase inhibitors
WO2003065982A3 (en) Engineering absorption of therapeutic compounds via colonic transporters
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
UA89035C2 (ru) Эфиры гидроксамовых кислот и их фармацевтическое применение
UA88270C2 (ru) Фармацевтический препарат и его применение для профилактики удара, диабета
IL300151A (en) Combinations for the treatment of cancer
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
CY1106763T1 (el) Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
MEP54608A (en) Arylmethylamine derivatives for use as tryptase inhibitors
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
PT1150704E (pt) Melagatran para o tratamento da inflamacao
SI1750703T1 (sl) Postopek za zmanjšanje gastrointestinalne toksičnosti zaradi dajanja tegafurja